Published in Lancet Oncol on December 01, 2007
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol (2009) 2.56
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica (2009) 1.50
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer (2010) 1.14
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk (2013) 1.08
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer (2010) 0.95
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood (2011) 0.95
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia (2008) 0.93
Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med (2010) 0.82
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica (2012) 0.80
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica (2016) 0.79
Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncol Lett (2016) 0.78
Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia. Rev Bras Hematol Hemoter (2011) 0.75
Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif (2017) 0.75
Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells. PLoS One (2014) 0.75
Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach. J Cancer Prev (2017) 0.75
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol (2007) 3.37